Galera Announces Updated Data from its Randomized, Multicenter, Placebo-Controlled Trial in Patients with Pancreatic Cancer
April 28, 2021 16:01 ET
|
Galera Therapeutics
Near double the median overall survival observed in patients receiving Galera’s dismutase mimetic + SBRT versus placebo + SBRT, showing strong therapeutic potential Improvements versus placebo also...
Galera Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Accomplishments
March 11, 2021 07:00 ET
|
Galera Therapeutics
Pivotal Phase 3 ROMAN Trial in Severe Oral Mucositis on Track for Completion of Enrollment in 1H21; Topline Data Readout in 2H21 Anticipate Final Data Readout from Locally Advanced Pancreatic...
Galera Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference
March 10, 2021 08:00 ET
|
Galera Therapeutics
MALVERN, Pa., March 10, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 20, 2020 08:00 ET
|
Galera Therapeutics
MALVERN, Pa., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates
November 10, 2020 07:00 ET
|
Galera Therapeutics
Presented Promising Interim Data from Placebo-controlled Pilot Dismutase Mimetic SBRT Combination Trial for Pancreatic Cancer Announced Planned Phase 2b GC4711 SBRT Combination Trial for Pancreatic...
Galera Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference
November 03, 2020 08:00 ET
|
Galera Therapeutics
MALVERN, Pa., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Therapeutics Announces Interim Data from Pilot Phase 1/2 Trial of GC4419 in Combination with Stereotactic Body Radiation Therapy Showed Improved Overall Survival in Patients with Locally Advanced Pancreatic Cancer
October 27, 2020 15:00 ET
|
Galera Therapeutics
Initial results from pilot Phase 1/2 clinical trial in patients with locally advanced pancreatic cancer presented during virtual ASTRO Annual Meeting First trial to evaluate anti-cancer activity...
Galera Therapeutics Announces Positive Interim Data from First Cohort of Patients in Pilot Phase 1/2 Clinical Trial of GC4419 in Pancreatic Cancer
October 23, 2020 17:00 ET
|
Galera Therapeutics
Interim data on first 19 patients released in ASTRO Annual Meeting late-breaker presentation abstract showed improvement in overall survival and multiple anti-cancer efficacy measures Interim...
Galera Therapeutics Announces Dosing of First Patient in the Phase 1/2 GRECO-1 Clinical Trial of GC4711 in Combination with SBRT for Non-Small Cell Lung Cancer
October 22, 2020 08:00 ET
|
Galera Therapeutics
MALVERN, Pa., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera Therapeutics to Host Virtual KOL Event on the Treatment of Locally Advanced Pancreatic Cancer
September 22, 2020 08:00 ET
|
Galera Therapeutics
MALVERN, Pa., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...